Abstract
Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Anti-Cancer Agents in Medicinal Chemistry
Title: The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies
Volume: 8 Issue: 6
Author(s): Vineet Pande, Maria J. Ramos and Federico Gago
Affiliation:
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Abstract: Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Export Options
About this article
Cite this article as:
Pande Vineet, Ramos J. Maria and Gago Federico, The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/187152008785133056
DOI https://dx.doi.org/10.2174/187152008785133056 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry DNA Base Excision Repair: The Achilles' Heel of Tumour Cells and their Microenvironment?
Current Pharmaceutical Design Long-term Exposure to Cadmium in Food and Cigarette Smoke, Liver Effects and Hepatocellular Carcinoma
Current Drug Metabolism Drug Metabolism and Pharmacokinetics of Dammarane Triterpenoids
Current Drug Metabolism Modulation of Mitochondrial and Epigenetic Targets by Polyphenols-rich Extract from Araucaria angustifolia in Larynx Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Effect of Extra Virgin Olive Oil and Table Olives on the ImmuneInflammatory Responses: Potential Clinical Applications
Endocrine, Metabolic & Immune Disorders - Drug Targets A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Medicinal Chemistry Microwave-Assisted Multicomponent Reactions in the Heterocyclic Chemistry
Current Organic Chemistry Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Emerging Role of G-quadruplex DNA as Target in Anticancer Therapy
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Drug Targets The University of New Mexico Center for Molecular Discovery
Combinatorial Chemistry & High Throughput Screening Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology From the RB Tumor Suppressor to MCR Peptides
Protein & Peptide Letters